Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Creative Medical (TASE:BLWV) Technology Holdings Inc. (CELZ) stock has reached a 52-week low, dipping to $1.95. With a market capitalization of just $3.85 million, the micro-cap company’s stock shows high volatility, as indicated by its beta of 4.6. According to InvestingPro analysis, the stock appears undervalued at current levels. This price level reflects a significant downturn for the company, which has experienced a -60.97% change over the past year. While investors closely monitor CELZ through this challenging period, the company maintains financial stability with more cash than debt on its balance sheet and a strong current ratio of 18.73. InvestingPro subscribers have access to 8 additional key insights about CELZ’s financial health and growth prospects, helping inform investment decisions in this volatile market environment.
In other recent news, Creative Medical Technology Holdings, Inc. has announced significant advancements across various initiatives. The company reported that the FDA has approved an expanded dose escalation for its Phase 1/2 StemSpine® trial, which aims to treat chronic lower back pain. Interim data from the trial has shown promising results, including significant pain reduction and improved mobility among participants. Additionally, Creative Medical Technology has secured $3.7 million through the immediate exercise of warrants, facilitated by Roth Capital Partners (WA:CPAP), which will be used for working capital and general corporate purposes.
The company also shared encouraging one-year follow-up results from its AlloStem™ Type 2 Diabetes pilot study, demonstrating an 80% efficacy rate in reducing insulin dependency. In a strategic move, Creative Medical has partnered with Greenstone Biosciences Inc. to integrate Artificial Intelligence into its stem cell platform for diabetes treatment, potentially reducing research and development time. Furthermore, the company has increased its authorized shares of common stock from 5 million to 25 million, following stockholder approval. These developments reflect Creative Medical Technology’s ongoing efforts to advance its regenerative medicine initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.